Diabetology & Metabolic Syndrome (Oct 2009)

TCF7L2 polymorphisms and inflammatory markers before and after treatment with fenofibrate

  • Kabagambe Edmond K,
  • Glasser Stephen P,
  • Ordovas Jose M,
  • Warodomwichit Daruneewan,
  • Tsai Michael Y,
  • Hopkins Paul N,
  • Borecki Ingrid B,
  • Wojczynski Mary,
  • Arnett Donna K

DOI
https://doi.org/10.1186/1758-5996-1-16
Journal volume & issue
Vol. 1, no. 1
p. 16

Abstract

Read online

Abstract Background Inflammation is implicated in causing diabetes. We tested whether transcription factor 7 like-2 (TCF7L2) gene polymorphisms (rs12255372 and rs7903146), consistently associated with type 2 diabetes, are associated with plasma concentrations of inflammatory markers before and after three weeks of daily treatment with fenofibrate. Methods Men and women in the Genetics of Lipid-Lowering Drugs and Diet Network study (n = 1025, age 49 ± 16 y) were included. All participants suspended use of lipid-lowering drugs for three weeks and were then given 160 mg/day of fenofibrate for three weeks. Inflammatory markers and lipids were measured before and after fenofibrate. ANOVA was used to test for differences across TCF7L2 genotypes. Results Under the additive or dominant model, there were no significant differences (P > 0.05) in the concentrations of inflammatory markers (hsCRP, IL-2, IL-6, TNF-α and MCP-1) across TCF7L2 genotypes in the period before or after treatment. For both rs12255372 and rs7903146, homozygote T-allele carriers had significantly higher (P Conclusion Overall these data show no association between TCF7L2 polymorphisms and the inflammatory markers suggesting that the effects of TCF7L2 on diabetes may not be via inflammation.